A Potential Breakthrough Therapy for Metabolic Disorders and Type 2 Diabetes
PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that controls whole-body energy metabolism and plays an important role in metabolic diseases and the management of diabetes. Compounds that directly target AMP kinase normalize glycemia and lipid profiles by:
- Increasing glucose uptake independently of insulin
- Increasing lipid oxidation
- Decreasing glucose and lipid production, restoring energy balance
In addition to its anti-diabetic properties, PXL770 has the potential to treat lipid-related abnormalities (cholesterol, triglycerides), which are present in a vast majority of diabetic patients and are the cause of cardiovascular incidents among this population (65% of deaths among diabetics are due to cardiovascular events*).
* Source: Centers for Disease Control (CDC): www.cdc.gov
Benefits: Targeting Cardiovascular Risk Factors
We observed several benefits on metabolic parameters in various animal models such as improved glucose and lipid profiles, as well as a benefit on weight. Other benefits include:
- A dose dependent A1c reduction
- A dose dependent benefit on weight
- A dose dependent plasma triglycerides reduction
- A dose dependent liver triglycerides reduction
PXL770 is in Phase 1.
PXL770 will be tested for safety, tolerability and pharmacokinetics
- Metabolite identification and qualification
- Safety, tolerability and pharmacokinetics after single and multiple ascending doses
PXL770 has the potential to be studied in several metabolic disorders, including liver and kidney diseases, as well as type 2 diabetes in a proof-of-concept program.
- Glycemic parameters (FPG, OGTT)
- Other cardiovascular risks: lipids, weight, inflammation
- Safety in target population
- AMPK biomarker in type 2 diabetes patients
Our Development and Commercialization Strategy
PXL770, as a first-in-class novel mechanism, provides a unique opportunity for patients with metabolic disorders and type 2 diabetes with high cardiovascular risk. Our Phase 1 trial will assess safety, tolerability and pharmacokinetics.